1. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors by Lecia V. Sequist, Belinda A. Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B. Turke, Panos Fidias, Kristin Bergethon, Alice T. Shaw, Scott Gettinger, Arjola K. Cosper, Sara Akhavanfard, Rebecca S. Heist, Jennifer Temel, James G. Christensen, John C. Wain, Thomas J. Lynch, Kathy Vernovsky, Eugene J. Mark, Michael Lanuti, A. John Iafrate, Mari Mino-Kenudson, and Jeffrey A. Engelman Sci Transl Med Volume 3(75):75ra26-75ra26 March 23, 2011 Published by AAAS

2. Fig. 1 The frequency of observed drug resistance mechanisms. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS

3. Fig. 2 Acquired genetic amplifications in drug-resistant lung tumors. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS

4. Fig. 3 Drug resistance and transformation of NSCLC to SCLC. The SCLC histological phenotype was observed in five (14%) NSCLC patients who had acquired resistance. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS

5. Fig. 4 EMT and acquired resistance. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS

6. Fig. 5 Longitudinal evaluation of patients treated repeatedly with erlotinib. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS